Skip to menu Skip to content Skip to footer
Associate Professor Joy Wolfram
Associate Professor

Joy Wolfram

Email: 

Overview

Background

Associate Professor Joy Wolfram leads an extracellular vesicle research program with the goal of developing innovative approaches that bring the next generation of medicines directly to the clinic to alter the trajectory of life-threatening diseases, improve patient outcomes, and prolong healthy lifespans. Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, Australia (#41 in Best Global Universities, U.S. News & World Report).

MISSION

1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer

2) Save lives by manufacturing at scale, by delivering national manufacturing innovation and a skilled workforce

3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine

Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional pharmaceuticals due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading of extracellular vesicles to develop therapeutics.

FOCUS AREAS

1) Developing improved methods for extracellular vesicle isolation from human biofluids

2) Designing hybrid drug delivery systems with extracellular vesicle and synthetic components for a ‘best-of-both-worlds’ approach to treat cardiovascular disease and aging kidney disease

3) Understanding the role of extracellular vesicles in cancer immunoevasion and metastasis

The research program has resulted in more than 100 publications in journals, such as, Nature Nanotechnology, Materials Today, and Nature Reviews Materials. These publications have been cited 16,800 times (Google Scholar). The Wolfram Laboratory has collaborated with 160 universities and industry partners across 45 countries (Scopus). The research program has also been featured in more than 100 presentations at scientific meetings, including 80+ invited talks and nine international keynote talks.

Wolfram is actively involved in community outreach and education, including in her previous roles as the Chair of an education and outreach working group of the National Institutes of Health in the United States and the Associate Program Director of the PhD Program in Regenerative Sciences at Mayo Clinic (Best Hospital in the World, Newsweek). As a TED speaker, she strives to bring science to a wide audience.

She has received 40+ awards from nine countries, including the 2016 Amgen Scholars Ten to Watch List (best and brightest up-and-comers in science and medicine across 42 countries), the 2019 Forbes 30 under 30 list in Health Care in the United States/Canada, the 2019 shortlist for the Nature Research Award for Inspiring Science (one of ten worldwide), and the 2021 Finnish Expatriate of the Year (past recipients include Nobel Memorial Prize winners, Millennium Technology Prize winners, and Formula 1 drivers). She is in the top 1% of researchers worldwide in the categories of ‘Biology & Biochemistry’ and ‘Pharmacology & Toxicology' (Essential Science Indicators, 2023) and in the top 0.5% in 'Extracellular Vesicles' (ScholarGPS 5/2024).

Availability

Associate Professor Joy Wolfram is:
Available for supervision
Media expert

Qualifications

  • Bachelor, University of Helsinki*
  • Masters (Coursework), University of Helsinki*
  • Doctor of Philosophy, University of the Chinese Academy of Science
  • Member, Global Young Academy, Global Young Academy
  • Honorary Academic, Houston Methodist Hospital, Houston Methodist Hospital
  • Member, The Swedish Academy of Engineering Sciences in Finland, The Swedish Academy of Engineering Sciences in Finland

Works

Search Professor Joy Wolfram’s works on UQ eSpace

236 works between 2009 and 2025

181 - 200 of 236 works

2017

Conference Publication

Center for immunotherapeutic transport oncophysics

Wolfram, Joy (2017). Center for immunotherapeutic transport oncophysics. 2017 Sage Assembly: Mapping Open Research Ecosystems, Seattle, WA, United States , April 2017.

Center for immunotherapeutic transport oncophysics

2017

Journal Article

Taking the vehicle out of drug delivery

Shen, Jianliang, Wolfram, Joy, Ferrari, Mauro and Shen, Haifa (2017). Taking the vehicle out of drug delivery. Materials Today, 20 (3), 95-97. doi: 10.1016/j.mattod.2017.01.013

Taking the vehicle out of drug delivery

2017

Conference Publication

Abstract B04: from modeling to in vivo tracking: a new platform for the design of delivery vectors that exploit tumor microfluidics

Nizzero, Sara, Litvinov, Sergey, Alexeev, Dmitry, Economides, Athena, Rosa, Enrica De, Wolfram, Joy, Koumoutsakos, Petros and Ferrari, Mauro (2017). Abstract B04: from modeling to in vivo tracking: a new platform for the design of delivery vectors that exploit tumor microfluidics. AACR Special Conference: Engineering and Physical Sciences in Oncology, Boston, MA USA, 25-28 June 2016. Philadelphia, PA USA: American Association for Cancer Research. doi: 10.1158/1538-7445.epso16-b04

Abstract B04: from modeling to in vivo tracking: a new platform for the design of delivery vectors that exploit tumor microfluidics

2017

Book Chapter

Nanomedicine activities in the United States and worldwide

Borsoi, Carlotta, Wolfram, Joy and Ferrari, Mauro (2017). Nanomedicine activities in the United States and worldwide. Nanoscience and nanotechnology for human health. (pp. 21-50) edited by Bert Müller and Marcel Van de Voorde. Weinheim, Germany: Wiley-VCH . doi: 10.1002/9783527692057.ch3

Nanomedicine activities in the United States and worldwide

2017

Journal Article

Post-nano strategies for drug delivery: multistage porous silicon microvectors

Venuta, Alessandro, Wolfram, Joy, Shen, Haifa and Ferrari, Mauro (2017). Post-nano strategies for drug delivery: multistage porous silicon microvectors. Journal of Materials Chemistry B, 5 (2), 207-219. doi: 10.1039/C6TB01978A

Post-nano strategies for drug delivery: multistage porous silicon microvectors

2017

Conference Publication

Porous silicon micropartciles for siRNA delivery

Wolfram, Joy, Shen, Jianliang, Shen, Haifa and Ferrari, Mauro (2017). Porous silicon micropartciles for siRNA delivery. RNA Nanotechnology Gordon Research Conference, Ventura, CA, United States , January 2017.

Porous silicon micropartciles for siRNA delivery

2016

Journal Article

Enzyme-responsive multistage vector for drug delivery to tumor tissue

Mi, Yu, Wolfram, Joy, Mu, Chaofeng, Liu, Xuewu, Blanco, Elvin, Shen, Haifa and Ferrari, Mauro (2016). Enzyme-responsive multistage vector for drug delivery to tumor tissue. Pharmacological Research, 113, 92-99. doi: 10.1016/j.phrs.2016.08.024

Enzyme-responsive multistage vector for drug delivery to tumor tissue

2016

Conference Publication

Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system (young investigator short talk)

Wolfram, Joy (2016). Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system (young investigator short talk). 7th Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium, Amelia Island, FL, United States , November 2016.

Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system (young investigator short talk)

2016

Conference Publication

Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system

Samuelsson, Emma, Nizzero, Sara, Blanco, Elvin, Shen, Haifa, Ferrari, Mauro and Wolfram, Joy (2016). Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system. 7th Mayo Clinic Angiogenesis and Tumor Microenvironment Symposium, Amelia Island, FL United States , November 2016.

Comparison of strategies for avoiding nanoparticle uptake by the mononuclear phagocyte system

2016

Journal Article

Label-free isothermal amplification assay for specific and highly sensitive colorimetric miRNA detection

Persano, Stefano, Guevara, Maria L., Wolfram, Joy, Blanco, Elvin, Shen, Haifa, Ferrari, Mauro and Pompa, Pier Paolo (2016). Label-free isothermal amplification assay for specific and highly sensitive colorimetric miRNA detection. ACS Omega, 1 (3), 448-455. doi: 10.1021/acsomega.6b00109

Label-free isothermal amplification assay for specific and highly sensitive colorimetric miRNA detection

2016

Conference Publication

TSH-nanoliposomes: a thyroid targeted nanomedicine

Paolino, Donatella, Cosco, D., Cilurzo, F., Gaspari, M., Celia, Christian, Failla, P., Wolfram, Joy, Celano, M., Fresta, Massimo and Russo, D. (2016). TSH-nanoliposomes: a thyroid targeted nanomedicine. XXIII National Meeting on Medicinal Chemistry, Fisciano, Italy , September 2015.

TSH-nanoliposomes: a thyroid targeted nanomedicine

2016

Journal Article

A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells

Scott, Bronwyn, Shen, Jianliang, Nizzero, Sara, Boom, Kathryn, Persano, Stefano, Mi, Yu, Liu, Xuewu, Zhao, Yuliang, Blanco, Elvin, Shen, Haifa, Ferrari, Mauro and Wolfram, Joy (2016). A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells. Pharmacological Research, 111, 413-421. doi: 10.1016/j.phrs.2016.07.005

A pyruvate decarboxylase-mediated therapeutic strategy for mimicking yeast metabolism in cancer cells

2016

Journal Article

Hesperetin liposomes for cancer therapy

Wolfram, Joy, Scott, Bronwyn, Boom, Kathryn, Shen, Jianliang, Borsoi, Carlotta, Suri, Krishna, Grande, Rossella, Fresta, Massimo, Celia, Christian, Zhao, Yuliang, Shen, Haifa and Ferrari, Mauro (2016). Hesperetin liposomes for cancer therapy. Current Drug Delivery, 13 (5), 711-719. doi: 10.2174/1567201812666151027142412

Hesperetin liposomes for cancer therapy

2016

Conference Publication

Super stealth liposomes for drug delivery

Wolfram, Joy (2016). Super stealth liposomes for drug delivery. European and Global Summit for Clinical Nanomedicine and Targeted Medicine, Basel, Switzerland , June 2016.

Super stealth liposomes for drug delivery

2016

Conference Publication

Multistage delivery of siRNA

Wolfram, Joy (2016). Multistage delivery of siRNA. European Summit for Clinical Nanomedicine and Targeted Medicine, Basel, Switzerland , June 2016.

Multistage delivery of siRNA

2016

Journal Article

A micro/nano composite for combination treatment of melanoma lung metastasis

Mi, Yu, Mu, Chaofeng, Wolfram, Joy, Deng, Zaian, Hu, Tony Ye, Liu, Xuewu, Blanco, Elvin, Shen, Haifa and Ferrari, Mauro (2016). A micro/nano composite for combination treatment of melanoma lung metastasis. Advanced Healthcare Materials, 5 (8), 936-946. doi: 10.1002/adhm.201500910

A micro/nano composite for combination treatment of melanoma lung metastasis

2016

Conference Publication

Nanoliposomes as multidrug therapy for anticancer treatment

Celia, Christian, Huang, Y., Paolino, Donatella, Cosco, D., Wolfram, Joy, Di Marzio, Luisa, Cilurzo, F., Cristiano, M. C., Shen, Haifa and Fresta, Massimo (2016). Nanoliposomes as multidrug therapy for anticancer treatment. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow, United Kingdom, April 2016.

Nanoliposomes as multidrug therapy for anticancer treatment

2015

Journal Article

Multistage vector (MSV) therapeutics

Wolfram, Joy, Shen, Haifa and Ferrari, Mauro (2015). Multistage vector (MSV) therapeutics. Journal of Controlled Release, 219, 406-415. doi: 10.1016/j.jconrel.2015.08.010

Multistage vector (MSV) therapeutics

2015

Journal Article

Multistage vector delivery of sulindac and silymarin for prevention of colon cancer

Scavo, Maria Principia, Gentile, Emanuela, Wolfram, Joy, Gu, Jianhua, Barone, Michele, Evangelopoulos, Michael, Martinez, Jonathan O., Liu, Xuewu, Celia, Christian, Tasciotti, Ennio, Vilar, Eduardo and Shen, Haifa (2015). Multistage vector delivery of sulindac and silymarin for prevention of colon cancer. Colloids and Surfaces B: Biointerfaces, 136, 694-703. doi: 10.1016/j.colsurfb.2015.10.005

Multistage vector delivery of sulindac and silymarin for prevention of colon cancer

2015

Journal Article

Recent advances in discovering the role of CCL5 in metastatic breast cancer

Khalid, Ayesha, Wolfram, Joy, Ferrari, Ilaria, Mu, Chaofeng, Mai, Junhua, Yang, Zhizhou, Zhao, Yuliang, Ferrari, Mauro, Ma, Xiaojing and Shen, Haifa (2015). Recent advances in discovering the role of CCL5 in metastatic breast cancer. Mini-Reviews in Medicinal Chemistry, 15 (13), 1063-1072. doi: 10.2174/138955751513150923094709

Recent advances in discovering the role of CCL5 in metastatic breast cancer

Funding

Current funding

  • 2025 - 2028
    Deciphering the role of muscle-derived extracellular vesicles in ALS pathology
    Cure for MND Foundation - Discovery Research Grants
    Open grant
  • 2025 - 2028
    Extracellular vesicle therapeutics for cardiac surgery-induced inflammation
    National Heart Foundation Future Leader Fellowship
    Open grant
  • 2024 - 2027
    Treating breast cancer metastasis by targeting immunosuppressive extracellular vesicles
    National Breast Cancer Foundation
    Open grant
  • 2023 - 2026
    Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease (NIH grant administered by Mayo Clinic)
    Mayo Clinic
    Open grant
  • 2023 - 2025
    Studying the basis of and developing new therapies to treat heart disease
    IPF Healthy - Medical Research
    Open grant
  • 2023 - 2026
    Personalising Innate-immunotherapy for Superior Treatment Outcomes with Large anticancer applicability (PISTOL)
    NHMRC MRFF EMCR - Early to Mid-Career Researchers
    Open grant

Past funding

  • 2024
    Monolithic chromatography for improved isolation of plasma-derived extracellular vesicles - Phase 2
    SARTORIUS STEDIM AUSTRALIA PTY. LTD
    Open grant
  • 2024
    Australia-United States Breast Cancer Consumer Workshop in Queensland
    Health Translation Queensland
    Open grant
  • 2023 - 2024
    CIMmultus Chromatographic Monolithic Columns for Isolation of Extracellular Vesicles from Plasma - Phase 1
    SARTORIUS STEDIM AUSTRALIA PTY. LTD
    Open grant
  • 2022 - 2024
    Going viral with extracellular vesicles: virus biology informs next-generation EV therapeutics
    Ionis Pharmaceuticals - Ion-ARPA Program Operation Payload Delivery
    Open grant

Supervision

Availability

Associate Professor Joy Wolfram is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Developing extracellular vesicle therapeutics for cardiovascular inflammation

    Every 12 minutes, one Australian dies of cardiovascular disease, accounting for 40,000+ annual deaths at a cost of $11.8B/year. Want to help us develop treatments for cardiovascular disease, the leading cause of death worldwide?

    Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for inflammatory cardiovascular disease.

    Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of cardiovascular disease, improve patient outcomes, and prolong healthy lifespan.

    This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat cardiovascular disease.

    LONG-TERM GOALS

    1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat cardiovascular inflammation.

    2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

  • Developing extracellular vesicle therapeutics for aging kidney disease

    In the upcoming decades, health care systems are predicted to collapse due to aging-associated diseases. Chronickidney disease is on the rise in the aging population and currently affects an estimated 1.7M Australians at a cost of $1.9B annually.

    Want to help us develop treatments for aging kidney disease? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle therapeutics for aging kidney disease.

    Extracellular vesicles are small biomolecular packages that are crucial for intercellular communication (locally and systemically). Extracellular vesicles have promising potential to be leveraged and engineered to provide a new paradigm of therapeutics that outperform conventional medicines due to versatile bioactive cargo. The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and drug loading (including RNA) of extracellular vesicles to alter the trajectory of aging diabetic kidney disease, improve patient outcomes, and prolong healthy lifespan.

    This project involves designing hybrid drug delivery systems with extracellular vesicles and synthetic components for a 'best-of-both-worlds' approach to treat aging kidney disease.

    LONG-TERM GOALS

    1) Develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat aging kidney disease.

    2) Save lives by manufacturing at scale - Deliver national manufacturing innovation and a skilled workforce.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

  • Understanding the contribution of extracellular vesicles in breast cancer immunoevasion

    The deadliest breast cancer is the triple-negative subtype, which has few treatment options. New treatments are urgently needed to prevent deaths and improve the quality of life for the 3,000 Australians who are diagnosed with triple-negative breast cancer every year.

    Want to help us develop treatments for deadly breast cancer? Now is your chance. I have an exciting PhD project in my lab for domestic scholars (Australian citizens/permanent residents) looking to make their mark in the ground-breaking field of extracellular vesicle-informed understanding and therapeutics for breast cancer.

    The immune system is known to play a critical role in detecting and eliminating breast cancer cells and the Wolfram Laboratory has shown that triple-negative breast cancer cells release extracellular vesicles with harmful biomolecules that help the cancer cells avoid detection and destruction by the immune system. The project involves assessing how these extracellular vesicles affect the ability of immune cells to destroy breast cancer cells. The project also involves the development of new treatment options for breast cancer, including engineering natural killer cells to be resistant to extracellular vesicle-mediated suppression.

    The Wolfram Laboratory is leveraging innovations in manufacturing, biological mechanisms, and targeting of extracellular vesicles to alter the trajectory of breast cancer, improve patient outcomes, and prolong healthy lifespan.

    LONG-TERM GOALS

    1) Uncover the mechanisms by which breast cancer extracellular vesicles suppress the immune system.

    2) Develop a new paradigm of therapeutics (using engineered immune cells) to treat triple negative breast cancer.

    3) Work with a multidisciplinary team and industry partners to position Australia as a global leader in extracellular vesicle medicine.

Supervision history

Current supervision

  • Doctor Philosophy

    Maximising the success of cancer immunotherapy by preventing extracellular vesicle hijacking of the immune system

    Principal Advisor

    Other advisors: Dr Allie Lam, Dr Zhengni Liu

  • Doctor Philosophy

    The extracellular vesicle bio-nano interactome in cancer metastasis.

    Principal Advisor

  • Doctor Philosophy

    Extracellular vesicle-based senotherapeutics for aging diabetic kidney disease

    Principal Advisor

    Other advisors: Dr Zhengni Liu

  • Doctor Philosophy

    Mutation Targeting Therapy for Cancer with dCas9

    Principal Advisor

  • Doctor Philosophy

    Engineered Extracellular Vesicles for Synergistic Myocardial Infarction Therapy

    Principal Advisor

Media

Enquiries

Contact Associate Professor Joy Wolfram directly for media enquiries about:

  • Biomanufacturing
  • Bioseparation
  • Biotherapeutics
  • Breast cancer
  • Exosomes
  • Extracellular vesicles
  • Nanomedicine
  • Nanoparticles
  • Regenerative medicine
  • Scientific outreach

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au